Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Target Price at $34.50

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $34.50.

NRXP has been the subject of several recent analyst reports. Wall Street Zen cut shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. D. Boral Capital reissued a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 10th. BTIG Research lowered their price objective on NRx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th.

NRx Pharmaceuticals Stock Performance

NRXP opened at $3.43 on Friday. The company has a market cap of $124.27 million, a price-to-earnings ratio of -6.24 and a beta of 2.18. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05. The business’s fifty day moving average is $3.78 and its two-hundred day moving average is $2.97.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The business had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. On average, analysts predict that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ethos Financial Group LLC lifted its holdings in shares of NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after acquiring an additional 4,000 shares during the period. Global Retirement Partners LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $107,000. Two Sigma Investments LP increased its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. State Street Corp increased its position in NRx Pharmaceuticals by 14.0% during the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Bleakley Financial Group LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter worth approximately $318,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.